当前位置： SCI文献检索 > BREAST CANCER RESEARCH期刊下所有文献 > Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth.

Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth.

Abstract：

INTRODUCTION:Human epidermal growth factor receptor HER3 has been implicated in promoting the aggressiveness and metastatic potential of breast cancer. Upregulation of HER3 has been found to be a major mechanism underlying drug resistance to EGFR and HER2 tyrosine kinase inhibitors and to endocrine therapy in the treatment of breast cancer. Thus, agents that reduce HER3 expression at the plasma membrane may synergize with current therapies and offer a novel therapeutic strategy to improve treatment. METHODS:We devised an image-based screening platform using membrane localized HER3-YFP to identify small molecules that promote HER3 internalization and degradation. In vitro and in vivo tumor models were used to characterize the signaling effects of perhexiline, an anti-anginal drug, identified by the screening platform. RESULTS:We found perhexiline, an anti-anginal drug, selectively internalized HER3, decreased HER3 expression, and subsequently inhibited signaling downstream of HER3. Consistent with these results, perhexiline inhibited breast cancer cell proliferation in vitro and tumor growth in vivo. CONCLUSIONS:This is the first demonstration that HER3 can be targeted with small molecules by eliminating it from the cell membrane. The novel approach used here led to the discovery that perhexiline ablates HER3 expression, and offers an opportunity to identify HER3 ablation modulators as innovative therapeutics to improve survival in breast cancer patients.

journal_name

Breast Cancer Res

journal_title

Breast cancer research : BCR

authors

Ren XR,Wang J,Osada T,Mook RA Jr,Morse MA,Barak LS,Lyerly HK,Chen W

doi

10.1186/s13058-015-0528-9

subject

Has Abstract

pub_date

2015-02-15 00:00:00

pages

20

eissn

1465-5411

issn

1465-542X

pii

s13058-015-0528-9

journal_volume

17

pub_type

杂志文章

相关文献

BREAST CANCER RESEARCH文献大全
  • Efficient treatment of breast cancer xenografts with multifunctionalized iron oxide nanoparticles combining magnetic hyperthermia and anti-cancer drug delivery.

    abstract：INTRODUCTION:Tumor cells can effectively be killed by heat, e.g. by using magnetic hyperthermia. The main challenge in the field, however, is the generation of therapeutic temperatures selectively in the whole tumor region. We aimed to improve magnetic hyperthermia of breast cancer by using innovative nanoparticles whi...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-015-0576-1

    authors： Kossatz S,Grandke J,Couleaud P,Latorre A,Aires A,Crosbie-Staunton K,Ludwig R,Dähring H,Ettelt V,Lazaro-Carrillo A,Calero M,Sader M,Courty J,Volkov Y,Prina-Mello A,Villanueva A,Somoza Á,Cortajarena AL,Miranda R,Hilge

    更新日期：2015-05-13 00:00:00

  • Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study.

    abstract：BACKGROUND:The global observational BREAKOUT study investigated germline BRCA mutation (gBRCAm) prevalence in a population of patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). METHODS:Eligible patients had initiated first-line cytotoxic chemotherapy for HER2-negativ...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,多中心研究

    doi：10.1186/s13058-020-01349-9

    authors： O'Shaughnessy J,Brezden-Masley C,Cazzaniga M,Dalvi T,Walker G,Bennett J,Ohsumi S

    更新日期：2020-10-27 00:00:00

  • Vitamin D and breast cancer: interpreting current evidence.

    abstract：:Preclinical investigations and selected clinical observational studies support an association between higher vitamin D intake and 25-hydroxyvitamin D levels with lower breast cancer risk. However, the recently updated report from the Institute of Medicine concluded that, for cancer and vitamin D, the evidence was 'inc...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/bcr2846

    authors： Chlebowski RT

    更新日期：2011-08-16 00:00:00

  • New generation breast cancer cell lines developed from patient-derived xenografts.

    abstract：BACKGROUND:Breast cancer is a highly heterogeneous disease characterized by multiple histologic and molecular subtypes. While a myriad of breast cancer cell lines have been developed over the past 60 years, estrogen receptor alpha (ER)+ disease and some mutations associated with this subtype remain underrepresented. He...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-020-01300-y

    authors： Finlay-Schultz J,Jacobsen BM,Riley D,Paul KV,Turner S,Ferreira-Gonzalez A,Harrell JC,Kabos P,Sartorius CA

    更新日期：2020-06-23 00:00:00

  • Mena deficiency delays tumor progression and decreases metastasis in polyoma middle-T transgenic mouse mammary tumors.

    abstract：INTRODUCTION:The actin binding protein Mammalian enabled (Mena), has been implicated in the metastatic progression of solid tumors in humans. Mena expression level in primary tumors is correlated with metastasis in breast, cervical, colorectal and pancreatic cancers. Cells expressing high Mena levels are part of the tu...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr2784

    authors： Roussos ET,Wang Y,Wyckoff JB,Sellers RS,Wang W,Li J,Pollard JW,Gertler FB,Condeelis JS

    更新日期：2010-01-01 00:00:00

  • Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study.

    abstract：INTRODUCTION:Primary breast cancer involving four or more axillary lymph nodes carries a poor prognosis. We hypothesized that use of an immunohistochemical biomarker scoring system could allow for identification of variable risk subgroups. METHODS:Patients with four or more positive axillary nodes were identified from...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,随机对照试验

    doi：10.1186/bcr1847

    authors： Crabb SJ,Bajdik CD,Leung S,Speers CH,Kennecke H,Huntsman DG,Gelmon KA

    更新日期：2008-01-01 00:00:00

  • Breast cancer prognosis by combinatorial analysis of gene expression data.

    abstract：INTRODUCTION:The potential of applying data analysis tools to microarray data for diagnosis and prognosis is illustrated on the recent breast cancer dataset of van 't Veer and coworkers. We re-examine that dataset using the novel technique of logical analysis of data (LAD), with the double objective of discovering patt...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr1512

    authors： Alexe G,Alexe S,Axelrod DE,Bonates TO,Lozina II,Reiss M,Hammer PL

    更新日期：2006-01-01 00:00:00

  • JMJD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHI.

    abstract：INTRODUCTION:Breast cancer is a worldwide health problem and the leading cause of cancer death among females. We previously identified Jumonji domain containing 2A (JMJD2A) as a critical mediator of breast cancer proliferation, migration and invasion. We now report that JMJD2A could promote breast cancer progression th...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr3667

    authors： Li LL,Xue AM,Li BX,Shen YW,Li YH,Luo CL,Zhang MC,Jiang JQ,Xu ZD,Xie JH,Zhao ZQ

    更新日期：2014-05-30 00:00:00

  • ELF5 isoform expression is tissue-specific and significantly altered in cancer.

    abstract：BACKGROUND:E74-like factor 5 (ELF5) is an epithelial-specific member of the E26 transforming sequence (ETS) transcription factor family and a critical regulator of cell fate in the placenta, pulmonary bronchi, and milk-producing alveoli of the mammary gland. ELF5 also plays key roles in malignancy, particularly in basa...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-015-0666-0

    authors： Piggin CL,Roden DL,Gallego-Ortega D,Lee HJ,Oakes SR,Ormandy CJ

    更新日期：2016-01-07 00:00:00

  • The clinical and functional significance of c-Met in breast cancer: a review.

    abstract：:c-Met is a receptor tyrosine kinase that upon binding of its ligand, hepatocyte growth factor (HGF), activates downstream pathways with diverse cellular functions that are important in organ development and cancer progression. Anomalous c-Met signalling has been described in a variety of cancer types, and the receptor...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/s13058-015-0547-6

    authors： Ho-Yen CM,Jones JL,Kermorgant S

    更新日期：2015-04-08 00:00:00

  • HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer.

    abstract：BACKGROUND:Tumor-derived extracellular vesicles (tdEVs) and circulating tumor cells (CTCs) in the blood of metastatic cancer patients associate with poor outcomes. In this study, we explored the human epidermal growth factor receptor 2 (HER2) expression on CTCs and tdEVs of metastatic breast cancer patients. METHODS:B...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-020-01323-5

    authors： Nanou A,Zeune LL,Bidard FC,Pierga JY,Terstappen LWMM

    更新日期：2020-08-12 00:00:00

  • In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis.

    abstract：BACKGROUND:Although recent models suggest that the detection of Circulating Tumor Cells (CTC) in epithelial-to-mesenchymal transition (EM CTC) might be related to disease progression in metastatic breast cancer (MBC) patients, current detection methods are not efficient in identifying this subpopulation of cells. Furth...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-016-0687-3

    authors： Bulfoni M,Gerratana L,Del Ben F,Marzinotto S,Sorrentino M,Turetta M,Scoles G,Toffoletto B,Isola M,Beltrami CA,Di Loreto C,Beltrami AP,Puglisi F,Cesselli D

    更新日期：2016-03-09 00:00:00

  • The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome.

    abstract：INTRODUCTION:Estrogens play a pivotal role in the initiation and progression of breast cancer. The genes that mediate these processes are not fully defined, but potentially include the known mammary oncogene MYC. Characterization of estrogen-target genes may help to elucidate further the mechanisms of estrogen-induced ...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr1985

    authors： Butt AJ,Sergio CM,Inman CK,Anderson LR,McNeil CM,Russell AJ,Nousch M,Preiss T,Biankin AV,Sutherland RL,Musgrove EA

    更新日期：2008-01-01 00:00:00

  • Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion.

    abstract：BACKGROUND:We previously performed a case-control genome-wide association study in women treated with selective estrogen receptor modulators (SERMs) for breast cancer prevention and identified single nucleotide polymorphisms (SNPs) in ZNF423 as potential biomarkers for response to SERM therapy. The ZNF423rs9940645 SNP,...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-017-0890-x

    authors： Qin S,Ingle JN,Liu M,Yu J,Wickerham DL,Kubo M,Weinshilboum RM,Wang L

    更新日期：2017-08-18 00:00:00

  • ALK alteration is a frequent event in aggressive breast cancers.

    abstract：INTRODUCTION:Breast cancer is the most common female malignancy worldwide and, despite improvements in treatment modalities, there are increased chances of recurrence and metastasis in a substantial number of cases and it remains one of the major causes of mortality among female cancer patients. Anaplastic lymphoma kin...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-015-0610-3

    authors： Siraj AK,Beg S,Jehan Z,Prabhakaran S,Ahmed M,R Hussain A,Al-Dayel F,Tulbah A,Ajarim D,Al-Kuraya KS

    更新日期：2015-09-17 00:00:00

  • Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer.

    abstract：BACKGROUND:Although parity and age at first pregnancy are among the most known extrinsic factors that modulate breast cancer risk, their impact on the biology of subsequent breast cancer has never been explored in depth. Recent data suggest that pregnancy-induced tumor protection is different according to breast cancer...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-019-1111-6

    authors： Nguyen B,Venet D,Lambertini M,Desmedt C,Salgado R,Horlings HM,Rothé F,Sotiriou C

    更新日期：2019-02-15 00:00:00

  • Rack1 mediates tyrosine phosphorylation of Anxa2 by Src and promotes invasion and metastasis in drug-resistant breast cancer cells.

    abstract：BACKGROUND:Acquirement of resistance is always associated with a highly aggressive phenotype of tumor cells. Recent studies have revealed that Annexin A2 (Anxa2) is a key protein that links drug resistance and cancer metastasis. A high level of Anxa2 in cancer tissues is correlated to a highly aggressive phenotype. Inc...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-019-1147-7

    authors： Fan Y,Si W,Ji W,Wang Z,Gao Z,Tian R,Song W,Zhang H,Niu R,Zhang F

    更新日期：2019-05-22 00:00:00

  • Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers.

    abstract：INTRODUCTION:Endocrine therapies target oestrogenic stimulation of breast cancer (BC) growth, but resistance remains problematic. Our aims in this study were (1) to identify genes most strongly associated with resistance to endocrine therapy by intersecting global gene transcription data from patients treated presurgic...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-014-0447-1

    authors： Ribas R,Ghazoui Z,Gao Q,Pancholi S,Rani A,Dunbier A,Dowsett M,Martin LA

    更新日期：2014-10-31 00:00:00

  • Tyrosine kinase signalling in breast cancer: modulation of tyrosine kinase signalling in human breast cancer through altered expression of signalling intermediates.

    abstract：:The past decade has seen the definition of key signalling pathways downstream of receptor tyrosine kinases (RTKs) in terms of their components and the protein-protein interactions that facilitate signal transduction. Given the strong evidence that links signalling by certain families of RTKs to the progression of brea...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/bcr54

    authors： Kairouz R,Daly RJ

    更新日期：2000-01-01 00:00:00

  • Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.

    abstract：INTRODUCTION:Reliable predictive and prognostic markers for routine diagnostic purposes are needed for breast cancer patients treated with neoadjuvant chemotherapy. We evaluated protein biomarkers in a cohort of 116 participants of the GeparDuo study on anthracycline/taxane-based neoadjuvant chemotherapy for operable b...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1186/bcr2363

    authors： Darb-Esfahani S,Loibl S,Müller BM,Roller M,Denkert C,Komor M,Schlüns K,Blohmer JU,Budczies J,Gerber B,Noske A,du Bois A,Weichert W,Jackisch C,Dietel M,Richter K,Kaufmann M,von Minckwitz G

    更新日期：2009-01-01 00:00:00

  • MiR-7 reduces the BCSC subset by inhibiting XIST to modulate the miR-92b/Slug/ESA axis and inhibit tumor growth.

    abstract：BACKGROUND:Breast cancer stem cells (BCSCs) are typically seed cells of breast tumor that initiate and maintain tumor growth. MiR-7, as a cancer inhibitor, decreases the BCSC subset and inhibits tumor progression through mechanisms that remain unknown. METHODS:We examined miR-7 expression in breast cancer and develope...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-020-01264-z

    authors： Li M,Pan M,You C,Zhao F,Wu D,Guo M,Xu H,Shi F,Zheng D,Dou J

    更新日期：2020-03-06 00:00:00

  • Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO).

    abstract：INTRODUCTION:Mutations in BRCA1 and BRCA2 confer a high risk of breast cancer (BC), but the magnitude of this risk seems to vary according to the study and various factors. Although controversial, there are data to support the hypothesis of allelic risk heterogeneity. METHODS:We assessed variation in BC risk according...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr3218

    authors： Lecarpentier J,Noguès C,Mouret-Fourme E,Gauthier-Villars M,Lasset C,Fricker JP,Caron O,Stoppa-Lyonnet D,Berthet P,Faivre L,Bonadona V,Buecher B,Coupier I,Gladieff L,Gesta P,Eisinger F,Frénay M,Luporsi E,Lortholary A,

    更新日期：2012-07-03 00:00:00

  • Transforming growth factor-beta and breast cancer: Transforming growth factor-beta/SMAD signaling defects and cancer.

    abstract：:Transforming growth factor-beta (TGF-beta) is a tumor suppressor, the function of which is compromised in many types of human cancer, including breast cancer. The tumor suppressive effects of TGF-beta are caused by potent inhibition of cell proliferation due to cell cycle arrest in the G1 phase. Such antiproliferative...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/bcr42

    authors： Kretzschmar M

    更新日期：2000-01-01 00:00:00

  • Inflammation markers and cognitive performance in breast cancer survivors 20 years after completion of chemotherapy: a cohort study.

    abstract：BACKGROUND:Inflammation is an important candidate mechanism underlying cancer and cancer treatment-related cognitive impairment. We investigated levels of blood cell-based inflammatory markers in breast cancer survivors on average 20 years after chemotherapy and explored the relation between these markers and global co...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-018-1062-3

    authors： van der Willik KD,Koppelmans V,Hauptmann M,Compter A,Ikram MA,Schagen SB

    更新日期：2018-11-15 00:00:00

  • Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study.

    abstract：INTRODUCTION:Radiation exposure at a young age is one of the strongest risk factors for breast cancer. Germline mutations in genes involved in the DNA-damage repair pathway (DDRP) may render women more susceptible to radiation-induced breast cancer. METHODS:We evaluated the contribution of germline mutations in the DD...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr1668

    authors： Broeks A,Braaf LM,Huseinovic A,Nooijen A,Urbanus J,Hogervorst FB,Schmidt MK,Klijn JG,Russell NS,Van Leeuwen FE,Van 't Veer LJ

    更新日期：2007-01-01 00:00:00

  • Family history of later-onset breast cancer, breast healthy behavior and invasive breast cancer among postmenopausal women: a cohort study.

    abstract：INTRODUCTION:A family history of later-onset breast cancer (FHLBC) may suggest multi-factorial inheritance of breast cancer risk, including unhealthy lifestyle behaviors that may be shared within families. We assessed whether adherence to lifestyle behaviors recommended for breast cancer prevention--including maintaini...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr2727

    authors： Gramling R,Lash TL,Rothman KJ,Cabral HJ,Silliman R,Roberts M,Stefanick ML,Harrigan R,Bertoia ML,Eaton CB

    更新日期：2010-01-01 00:00:00

  • Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions.

    abstract：:A series of recent studies have demonstrated that the retinoblastoma tumor suppressor (RB) pathway plays a critical role in multiple clinically relevant aspects of breast cancer biology, spanning early stage lesions to targeted treatment of metastatic disease. In ductal carcinoma in situ, multiple groups have shown th...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/bcr3652

    authors： Witkiewicz AK,Knudsen ES

    更新日期：2014-05-07 00:00:00

  • Prenylation inhibitors stimulate both estrogen receptor alpha transcriptional activity through AF-1 and AF-2 and estrogen receptor beta transcriptional activity.

    abstract：INTRODUCTION:We showed in a previous study that prenylated proteins play a role in estradiol stimulation of proliferation. However, these proteins antagonize the ability of estrogen receptor (ER) alpha to stimulate estrogen response element (ERE)-dependent transcriptional activity, potentially through the formation of ...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr956

    authors： Cestac P,Sarrabayrouse G,Médale-Giamarchi C,Rochaix P,Balaguer P,Favre G,Faye JC,Doisneau-Sixou S

    更新日期：2005-01-01 00:00:00

  • Future possibilities in the prevention of breast cancer: fat and fiber and breast cancer research.

    abstract：:The potential for a reduction in dietary fat or for an increase in dietary fiber to reduce breast cancer risk has been debated for some years. It is argued here that available research data, even though extensive, leave open hypotheses ranging from little or no potential to major public health potential for breast can...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/bcr68

    authors： Prentice RL

    更新日期：2000-01-01 00:00:00

  • Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients.

    abstract：INTRODUCTION:The HER (human EGFR related) family of receptor tyrosine kinases (HER1/EGFR (epidermal growth factor receptor)/c-erbB1, HER2/c-erbB2, HER3/c-erbB3 and HER4/c-erbB4) shares a high degree of structural and functional homology. It constitutes a complex network, coupling various extracellular ligands to intrac...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr1843

    authors： Sassen A,Rochon J,Wild P,Hartmann A,Hofstaedter F,Schwarz S,Brockhoff G

    更新日期：2008-01-01 00:00:00